

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MARINUS PHARMACEUTICALS, INC.,
Petitioner,

v.

OVID THERAPEUTICS INC.,
Patent Owner.

Case PGR2023-00020
Patent 11,395,817 B2

PATENT OWNER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner Ovid Therapeutics Inc. hereby submits a current listing of Patent Owner exhibits. Exhibits 2014-2020 are being filed today.

Exhibit	Description
2001	Disclaimer in Patent Under 37 CFR 1.321(a) for claims 1-21 and 23-24 of U.S. Patent No. 11,395,817, filed June 16, 2023
2002	Marinus Corporate Presentation June 2023, https://s25.q4cdn.com/443656056/files/doc_financials/2023/Corporate-Deck-June-FINAL.pdf (last accessed June 19, 2023)
2003	H. Vaitkevicius et al., Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial, 63 <i>Epilepsia</i> 2381-2391 (2022)
2004	Ovid Therapeutics Corporate Overview May 2023, https://s201.q4cdn.com/176459324/files/doc_presentation/2023/05/OVID-May-2023-Corporate-Deck-FINAL-FOR-POSTING-5-5-23-1.pdf (last accessed June 19, 2023)
2005	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (March 21, 2022), https://ir.marinuspharma.com/news/news-details/2022/Marinus-Pharmaceuticals-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results/default.aspx (last accessed June 19, 2023)
2006	Excerpts from the File History of Provisional App. No. 62/882,648
2007	Excerpts from the File History of U.S. Patent No. 11,679,117
2008	Excerpts from the File History of U.S. Patent No. 11,110,100
2009	Excerpts from the File History of U.S. Patent No. 10,799,485
2010	Excerpts from the File History of U.S. Patent No. 10,603,308

Exhibit	Description
2011	Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board (April 30, 2020), https://s25.q4cdn.com/443656056/files/doc_news/Marinus-Pharmaceuticals-Announces-Formation-of-Scientific-Advisory-Board-2020.pdf (last accessed June 19, 2023)
2012	Marinus Scientific Advisory Board, https://marinuspharma.com/about-marinus/scientific-advisory-board/ (last accessed June 19, 2023)
2013	Excerpt from the File History of U.S. Patent No. 11,395,817
2014	Declaration of Raman Sankar, M.D., Ph.D
2015	Transcript of Deposition of Dr. Michael A. Rogawski (November 15, 2023)
2016	Transcript of Deposition of Dr. Michael Saporito (November 7, 2023)
2017	European Medicines Agency, <i>Ztalmy Assessment Report</i> , EMA/267469/2023 (May 25, 2023)
2018	Tocris Bioscience, Ganaxolone Safety Data Sheet
2019	Lewis J. Fermaglich & Kathleen L. Miller, <i>A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act</i> , 18 Orphanet J. of Rare Diseases 163 (2023)
2020	Michele Simonato et al., <i>Issues for new antiepilepsy drug development</i> , Curr. Opin. Neurol. 195-200 (2013)

Respectfully submitted,

Dated: November 30, 2023

/Anthony C. Tridico/
Anthony C. Tridico, Reg. No. 45,958

Counsel for Patent Owner
Ovid Therapeutics Inc.

CERTIFICATE OF SERVICE

The undersigned certifies that a copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibits 2014-2020** were served electronically via email on November 30, 2023, in their entirety on the following:

Martina Tyreus Hufnal
Deanna Reichel
Anita L. Meiklejohn
Katie E. Hyma
Michael J. Kane
Fish & Richardson P.C.
60 South Sixth Street, Suite 3200
Minneapolis, MN 55402
PGR50689-0016PS1@fr.com (referencing Attorney Docket No. 50689-0016PS1)

Petitioner has consented to electronic service by email.

Dated: November 30, 2023

/William Esper/
William Esper
Case Manager and PTAB Coordinator
Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP